Journal: bioRxiv
Article Title: Homozygosity for rare or common hypomorphic IL23R variants confers a predisposition to tuberculosis in humans
doi: 10.64898/2026.03.23.713554
Figure Lengend Snippet: (A) Emitted luminescence measured in the presence of the NanoLuc inhibitor is expressed as a percentage of that measured in the absence of the inhibitor (100%), in HEK293T cells transiently transfected with N-terminal NanoLuciferase-tagged versions of the wildtype or variants of the IL-23 receptor (NLuc IL-23R, NLuc IL-23R R381Q, NLuc IL-23R G300V, NLuc IL-23R G149R, NLuc IL-23R L372F or NLuc IL-23R C115Y) and IL-12Rβ1 (4:1 ratio). The data shown are the mean ± SEM from 5-7 independent experiments conducted in triplicate wells. Statistical significance was determined in a paired t-test (*** P <0.001, * P <0.5). Data for NLuc IL-23R C115Y were obtained in a previous study. (B) HEK293T cells transiently transfected as described in A) were imaged with an Olympus LuminoView 200 wide-field luminescence microscope. Representative luminescence images show the signal originating from the N-terminal NLuc tag of each IL-23R variant following the addition of furimazine (final dilution 1:400). Data from three independent experiments are shown. The scale bar represents 50 μm. Luminescence images were acquired with a 60x NA1.42 oil immersion objective, a 0.5x tube lens, and a C9100-23B IMAGE EMX2 camera (Hamamatsu, Japan), with an exposure time of 20 s (gain of 25). (C) HEK293T cells transiently transfected as in A) were treated with various concentrations of fluorescently labeled IL-23 (IL-23-TAMRA) in the presence or absence of unlabeled IL-23. The NanoLuciferase substrate furimazine was then added (final concentration: 7.7 μM) and emitted luminescence and fluorescence were simultaneously detected with a BMG Pherastar FS. BRET ratios were calculated by subtracting fluorescence from luminescence. The specific binding of IL-23-TAMRA was calculated by subtracting BRET ratios determined in the presence of unlabeled IL-23 (non-specific binding) from those obtained in its absence. The data shown are the mean ± SEM ( n = 4-5 independent experiments performed in triplicate wells for NLuc IL-23R wildtype vs. NLuc IL-23R R381Q; n = 5 independent experiments performed in triplicate for NLuc IL-23R wildtype vs. NLuc IL-23R G300V; n = 5 independent experiments performed in duplicate for NLuc IL-23R wildtype vs. NLuc IL-23R G149R or NLuc IL23R L372F). (D) Representative results for pSTAT3 detection by western blotting after IL-23 stimulation (10 ng/mL) in EBV-B cell lines from healthy donors (HD: green), IL23R R381Q/R381Q (P12, P17, and P4: violet), IL23R G300V/G300V (P18, P19, and 20: orange) and IL23R LOF/LOF ( IL-23R -/- : red) patients. (E) Representative graph of multiple independent western-blot experiments showing pSTAT3/STAT3 band density. If there were several measurements on the same EBV-B cell lines, this is indicated in parentheses. (G) MFI of pSTAT3 normalized against non-stimulated T-blast cells from healthy donors (green dots), IL23R G149R/G149R (yellow dots), IL23R G300V/G300V (orange dots), IL23R R381Q/R381Q (purple dots), IL-12Rβ1- and IL-23R-deficient patients (blue and red dots, respectively) in the presence or absence of various concentrations of IL-23. IFNα2 stimulation (1 ng/mL) was used as a control. Statistical significance was assessed in unpaired Mann-Whitney’s U tests comparing each variant to HD or WT as appropriate. * p < 0.05, ** p <0.01, *** p <0.001, **** p <0.0001.
Article Snippet: Cells were incubated in the presence or absence of live BCG, at a multiplicity of infection of 1, with or without recombinant human IL-12 (5 ng/mL, R&D), recombinant human IL-18 (25 ng/mL, R&D) and/or recombinant human IL-23 (100 ng/mL, 1290-IL R&D Systems), or IFN-γ (5000 IU/mL).
Techniques: Transfection, Microscopy, Variant Assay, Labeling, Concentration Assay, Fluorescence, Binding Assay, Western Blot, Control